Prospective study on prognostic significance of DNA ploidy and Ki-67 expression in colorectal cancer

Journal of Biological Regulators and Homeostatic Agents

Volumn 21, Issue 1-2, 2007, Pages 13-21

  Santagostino, Alberto ^a   Saggia, C ^b   Migliora, P ^a   Pavanelli, M C ^a   Forti, G ^b   Biaggi, G ^a   Angeli, G ^a   Dacorsi, M ^a   Alabiso, O ^c  

^a SANT'ANDREA HOSPITAL   (Italy)

^b Dipartimento di Medicina Specialistica ASL 11   (Italy)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Colorectal cancer; Cytofluorimetric analysis; DNA ploidy; Ki 67 expression; Prognostic factors

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROFOLATE; FOLIC ACID DERIVATIVE; IRINOTECAN; KI 67 ANTIGEN; OXALIPLATIN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOMETRY; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PLOIDY; PREDICTION; PROGNOSIS; PROSPECTIVE STUDY; TREATMENT RESPONSE; UNIVARIATE ANALYSIS;

EID: 41949127880     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. De Vita VT. Cancer Principles & practice of oncology: Cancer of gastrointestinal tract: Cancer of the colon. 6Th ed Lippincott Williams & Wilkins, 2005; p. 1061.
2. Kouri M. DNA ploidy of colorectal carcinoma by tumour site, gender and history of noncolorectal malignancies. Oncology 1993; 50:41-5.
3. Yamamoto T, Matsumoto K, Yamamoto J et al. Clinical significance of DNA index in hematogenous dissemination of aneuploid colorectal cancer. Surg Today 1997; 27:973-4.
4. Risques RA, Moreno V, Marcuelllo E et al. Redefining the significance of aneuploidy in the prognostic assessment of colorectal cancer. Lab Invest 2001; 3:307-15.
5. Karelia NH, Patel DD, Desai NS et al. Prognostic significance of DNA aneuploidy expression in colorectal cancer and their role in the determination of treatment modalities. Int J Biol Markers 2001; 16:97-104.
6. Bendardaf R, Lamulum H, Ristamaki R et al. Response to chemotherapy (irinotecan plus 5-fluorouracil) in colorectal carcinoma can be predicted by tumour DNA content. Oncology 2004; 66:46-52.
7. Armitage NC, Robin RA, Evans DF et al. The influence of tumour cell DNA abnormalities on survival in colorectal cancer. Br J Surg 1985; 72:828-830.
8. Tang R, Ho YS, Hsu KC et al. Prognostic evaluation of DNA flow cytometric and histopathologic parameters of colorectal cancer. Cancer 1995; 76:1724-1730.
9. Lanza G, Gafà R, Santini A et al. Prognostic significance of DNA ploidy in patients with stage II and III colon carcinoma. Cancer 1998; 82:9-53.
10. Bauer KD, Bagwell GB, Giaretti W et al. Consensus Review of the clinical utility of DNA flow cytometry in colorectal cancer. Cytometry 1993; 14:486-391.
11. Sinicrope FA, Hart J, Hsu HA et al. Apoptotic and mitotic indices predict survival rates in lymph nodes-negative colon carcinomas. Clin Cancer Res 1999; 5:1793-1804.
12. Kimura T, Tanaka S, Hamura K et al. Clinical significance of MUC1 and E-cadherin expression, cellular proliferation and angiogenesis at the deepest invasive portion of colorectal cancer. Int J Oncol 2000; 16:55-64.
13. Garrity MM, Burgart LJ, Witzig TE et al. Prognostic value of proliferation, apoptosis, defective DNA Mismatch Repair, and p53 overexpression in patients with resected Duke's B2 or C colon cancer: a North Central Cancer Treatment Group Study. J Clin Oncol 2004; 22:1572-1582.
14. Cancer Guidance Sub-Group of the Clinical Outcomes Group. Improving outcomes in colorectal cancer: the research evidence. Leeds, NHS executive, 1997.